Eventide Asset Management - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$12,798,350
-22.7%
359,0000.0%0.23%
-17.9%
Q2 2023$16,560,670
+15.0%
359,0000.0%0.28%
+6.1%
Q1 2023$14,395,900
-13.4%
359,0000.0%0.26%
-19.5%
Q4 2022$16,632,470
+31.3%
359,000
+17.4%
0.33%
+31.7%
Q3 2022$12,663,000
+89.8%
305,800
+249.9%
0.25%
+1.6%
Q3 2018$6,672,000
-0.7%
87,4000.0%0.24%
-12.2%
Q2 2018$6,718,000
+50.7%
87,4000.0%0.28%
+33.5%
Q1 2018$4,457,000
+9.9%
87,4000.0%0.21%
-0.9%
Q4 2017$4,054,000
-12.9%
87,4000.0%0.21%
-20.1%
Q3 2017$4,655,000
-14.2%
87,4000.0%0.26%
-21.9%
Q2 2017$5,428,000
-8.4%
87,4000.0%0.34%
-13.8%
Q1 2017$5,924,000
-3.6%
87,4000.0%0.39%
-2.0%
Q4 2016$6,145,000
-0.9%
87,4000.0%0.40%
+5.5%
Q3 2016$6,200,000
+45.0%
87,4000.0%0.38%
+44.7%
Q2 2016$4,275,000
-22.7%
87,4000.0%0.26%
-15.2%
Q1 2016$5,533,000
-43.6%
87,4000.0%0.31%
-36.9%
Q4 2015$9,805,000
-3.5%
87,400
-17.2%
0.49%
-16.9%
Q3 2015$10,161,000
+18.0%
105,500
+25.4%
0.59%
+26.6%
Q2 2015$8,611,000
+101.0%
84,100
+21.9%
0.47%
+44.7%
Q1 2015$4,284,000
+85.6%
69,000
+31.2%
0.32%
+27.8%
Q4 2014$2,308,000
-22.5%
52,6000.0%0.25%
-39.4%
Q3 2014$2,977,000
+26.1%
52,6000.0%0.42%
+29.6%
Q2 2014$2,361,00052,6000.32%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2022
NameSharesValueWeighting ↓
First Light Asset Management, LLC 441,159$39,788,0002.62%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 103,100$9,286,0002.24%
Rock Springs Capital Management LP 801,109$72,252,0001.52%
Avidity Partners Management LP 455,000$41,036,0000.91%
Motley Fool Asset Management LLC 134,357$12,118,0000.79%
FEDERATED HERMES, INC. 3,987,032$359,590,0000.68%
EMERALD ADVISERS, LLC 196,124$17,688,0000.64%
Ergoteles LLC 128,100$11,553,0000.42%
Tekla Capital Management LLC 140,726$12,692,0000.41%
Beck Bode, LLC 14,990$1,352,0000.38%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders